NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Lipocine Inc. (LPCN) Stock Analysis

Lipocine Inc. (LPCN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

LPCN

$1.60

−$0.02 (−1.23%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare LPCN with… →

LPCN Key Statistics

As of Oct 21, 2026
Trading
Open
$1.59
Previous Close
$1.62
Day's Range
1.58–1.64
52-Week Range
1.40–12.37
Volume
159.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.40
Valuation
Market Cap
$13.19M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.40
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.85
Financials (FY)
Revenue (FY)
$1.98M−82.35%
Net Income (FY)
−$9.63M−115,371.85%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
8.24M
1-Year Return
−45.39%
Dividend and dates
Avg Volume
1.78M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, LPCN closed at $1.60, −45.39% over 1 year.

Lipocine Inc. (LPCN) has a market capitalization of $13.19M.

In fiscal 2025, LPCN reported revenue of $1.98M.

LPCN Stock Return by Calendar Year

Lipocine Inc. (LPCN) 10-year return: what $10,000 became

1 year
$10,000 $5,461
−45.39%
5 years
$10,000 $863
−91.37%
10 years
$10,000 $263
−97.37%

If you had invested $10,000 in Lipocine Inc. (LPCN) 10 years ago, at the close on October 21, 2016, it would have been worth $263 at the close on October 21, 2026: −97.37% in total, −30.50% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−80.07%
2025+64.55%
2024+74.91%
2023−58.76%
2022−59.84%
2021−27.13%
2020+253.25%
2019−70.38%
2018−62.21%
2017−6.52%
2016 (partial year)−0.27%

As of October 21, 2026.

LPCN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$1.98M−$9.63M−487.1%
2024$11.20M$8.35K0.1%
2023−$2.85M−$16.35M573.6%
2022$500.00K−$10.76M−2,151.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.98M−$6.61M−$10.37M−$9.63M−487.1%
2024$11.20M$3.85M−$1.16M$8.35K0.1%
2023−$2.85M−$13.03M−$17.93M−$16.35M573.6%
2022$500.00K−$8.06M−$12.12M−$10.76M−2,151.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

LPCN Valuation vs Biotechnology Median

Median of 608 stocks
MetricLPCNBiotechnology medianvs median
P/S ratio8.4013.3037% below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 14 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Lipocine Inc. (LPCN) is capitalised at $13.19M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 14.

The 52-week range on file runs from $1.40 to $12.37. The most recent close on file for LPCN is $1.60, dated October 21, 2026. That is −$0.02 (−1.23%) against the previous close. The latest close sits 14.29% above that 52-week low.

Financial Health

In fiscal 2025, Lipocine Inc. reported revenue of $1.98M. That is −82.35% against the prior fiscal year, when revenue was $11.20M. The same year closed with a net loss of $9.63M. Trailing earnings per share are −1.85.

Across the 4 fiscal years on file, revenue moves from $500.00K in 2022 to $1.98M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 8.4. On price-to-sales that is 36.8% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 0.4. Annualized volatility over the trailing 10 years is 87.14%. The trailing one-year total return is −45.39%. Measured over 10 years, that is −30.50% a year compounded.

Growth & Income

The record shows no dividend for LPCN.

So far in 2026 the total return is −80.07%. The strongest complete calendar year on file is 2020 at +253.25%; the weakest is 2019 at −70.38%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Lipocine Inc. (LPCN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Lipocine Inc. LPCN $13.19M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Lipocine Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Lipocine Inc.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Phase 2 trial for the management of decompensated cirrhosis; LPCN 1107, an oral hydroxy progesterone caproate product that has completed a Phase 2 trial for the prevention of recurrent preterm birth; LPCN 1144, an oral prodrug of bioidentical testosterone that has completed a Phase 2 trial for pre-cirrhotic non-alcoholic steatohepatitis; and LPCN 2401, an oral formulation comprising a proprietary anabolic androgen receptor agonist that is in a Phase 2 trial to manage incretin mimetic use in obesity management. In addition, the company is developing LPCN 2201, an oral brexanolone formulation that has completed a Phase 1 trial for major depressive disorders; LPCN 2203, an oral candidate that has completed a Phase 1 trial for management of essential tremor; and LPCN 2101, a neuroactive steroids (NAS) candidate that has completed a Phase 1 trial for drug-resistant epilepsy and women with epilepsy. The company's products focus on neurological and psychiatric central nervous system (CNS) disorders, liver disease, and hormone supplementation in the United States. It has a collaboration with Verity Pharmaceuticals, Inc. to develop and commercialize TLANDO; and TLANDO XR (LPCN 1111), a once-daily oral product candidate that has completed a Phase 2 trial for testosterone replacement therapy. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

Visit website →